healthcare system

Trump’s Tariffs on Pharmaceutical Industry: What Indian Companies Should Know

Summary: The U.S. has imposed 100% tariffs on branded and patented drug imports effective October 1, 2025. Although generic drugs remain exempt from these tariffs, the announcement marks a drastic change for pharmaceutical trade which has remained unrestricted for a long time. For Indian pharmaceutical companies supplying nearly half of all generic medicines consumed in the U.S., this development requires them to reassess their market strategies, compliance frameworks, and long-term supply chain planning to navigate an increasingly complex geopolitical environment.Continue Reading Trump’s Tariffs on Pharmaceutical Industry: What Indian Companies Should Know

U.S. Spotlight on Pharma Imports: What does this mean for Indian Pharma?

The U.S. Department of Commerce Bureau of Industry and Security (“BIS”), on April 14, 2025, announced the initiation of an investigation into the imports of pharmaceuticals and pharmaceutical ingredients as well as semiconductors and semiconductor manufacturing equipment in the context of U.S. national security. This move could affect India’s USD 10 billion annual pharmaceutical exports to the U.S.Continue Reading U.S. Spotlight on Pharma Imports: What does this mean for Indian Pharma?